Stryker Corporation $SYK is Richards Merrill & Peterson Inc.’s 10th Largest Position

Richards Merrill & Peterson Inc. raised its holdings in Stryker Corporation (NYSE:SYK) by 13.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 14,942 shares of the medical technology company’s stock after acquiring an additional 1,784 shares during the period. Stryker makes up approximately 2.0% of Richards Merrill & Peterson Inc.’s investment portfolio, making the stock its 10th largest position. Richards Merrill & Peterson Inc.’s holdings in Stryker were worth $5,252,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of SYK. Vanguard Group Inc. increased its holdings in shares of Stryker by 0.8% in the third quarter. Vanguard Group Inc. now owns 33,773,399 shares of the medical technology company’s stock valued at $12,485,012,000 after purchasing an additional 272,828 shares during the last quarter. Alliancebernstein L.P. grew its holdings in Stryker by 13.3% in the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock valued at $2,342,987,000 after buying an additional 741,542 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Stryker by 4.4% during the 3rd quarter. Legal & General Group Plc now owns 2,303,290 shares of the medical technology company’s stock worth $851,457,000 after acquiring an additional 96,662 shares during the period. Corient Private Wealth LLC raised its holdings in shares of Stryker by 104.4% during the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after acquiring an additional 1,146,998 shares during the period. Finally, Invesco Ltd. boosted its position in shares of Stryker by 4.5% during the 3rd quarter. Invesco Ltd. now owns 1,864,918 shares of the medical technology company’s stock valued at $689,404,000 after acquiring an additional 80,536 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 250,000 shares of Stryker stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the sale, the director owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.60% of the company’s stock.

Stryker Stock Down 1.5%

Shares of SYK opened at $338.15 on Tuesday. The firm has a market cap of $129.50 billion, a P/E ratio of 40.26, a price-to-earnings-growth ratio of 2.01 and a beta of 0.92. Stryker Corporation has a 12-month low of $319.32 and a 12-month high of $404.87. The company’s 50-day moving average price is $352.61 and its 200 day moving average price is $359.31. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, topping the consensus estimate of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The company had revenue of $7.17 billion during the quarter, compared to analyst estimates of $7.12 billion. During the same quarter last year, the firm posted $4.01 earnings per share. Stryker’s revenue was up 11.4% compared to the same quarter last year. On average, sell-side analysts forecast that Stryker Corporation will post 14.92 earnings per share for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. Stryker’s dividend payout ratio (DPR) is presently 41.90%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on SYK shares. BTIG Research reissued a “buy” rating and issued a $397.00 price objective on shares of Stryker in a report on Tuesday, April 14th. The Goldman Sachs Group decreased their target price on shares of Stryker from $403.00 to $357.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. TD Cowen cut shares of Stryker from a “buy” rating to a “hold” rating and set a $387.00 price target for the company. in a research note on Monday, January 26th. Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Saturday. Finally, UBS Group reduced their price target on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 17th. Fifteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $421.11.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.